BioWorld

Jan. 9, 2002

DeCode Adding Chemistry Via $83.6M MediChem Acquisition

Calling the move not only logical, but necessary, DeCode Genetics Inc. said it is buying MediChem Life Sciences Inc. in a stock swap worth about $83.6 million. Read More

Pharmacyclics: Xcytrin Works In Lung-Brain Metastasis Group

Iowa University, IntronnJoin To Correct Cystic Fibrosis Mutant Gene In Customized Mouse Mimic

IDEC Hits Manufacturing Snag With Zevalin; Trials Not Needed

Other News To Note

Signature Adding To Oncology Portfolio Via PrimeCyte Purchase

Enzon, Inhale Enter Broad Deal On Pegylation, Licensing, Lawsuit

Maxygen Partners With Celltech To Work On Antibody Programs

3-D Pharma In-Licenses Drug From GSK Through Stock Deal

Today's news in brief

BioWorld

BioWorld briefs for June 29, 2026.

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement

BioWorld Science

Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...

Investors bet on transformative BCI tech for neuro disorders

BioWorld

An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....